← Back to Screener
Briacell Therapeutics Corp. Common Shares (BCTX)
Price$4.02
Favorite Metrics
Price vs S&P 500 (26W)-73.30%
Price vs S&P 500 (4W)-2.65%
Market Capitalization$44.16M
All Metrics
Book Value / Share (Quarterly)$4.26
P/TBV (Annual)0.72x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-4.27
Price vs S&P 500 (YTD)-41.22%
EPS (TTM)$-32.56
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-32.56
EPS (Annual)$-62.19
ROI (Annual)-146.18%
Cash / Share (Quarterly)$4.12
ROA (Last FY)-119.60%
EBITD / Share (TTM)$-20.65
ROE (5Y Avg)-248.00%
Cash Flow / Share (Annual)$-14.98
P/B Ratio1.04x
P/B Ratio (Quarterly)0.89x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-1.32x
ROA (TTM)-138.95%
EV / EBITDA (TTM)0.52x
EPS Incl Extra (Annual)$-62.19
Current Ratio (Annual)5.03x
Quick Ratio (Quarterly)10.10x
3-Month Avg Trading Volume0.02M
52-Week Price Return-88.55%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.24
52-Week High$135.00
EPS Excl Extra (Annual)$-62.19
26-Week Price Return-64.55%
Quick Ratio (Annual)5.03x
13-Week Price Return-2.56%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.10x
Enterprise Value$2.336
Revenue / Employee (Annual)$0
Cash / Share (Annual)$9.57
3-Month Return Std Dev70.61%
Net Income / Employee (TTM)$-1
ROE (Last FY)-146.18%
Net Interest Coverage (Annual)-6.72x
EPS Basic Excl Extra (Annual)$-62.19
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-32.56
Receivables Turnover (Annual)0.00x
ROI (TTM)-166.53%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$9.60
Price vs S&P 500 (52W)-123.65%
Year-to-Date Return-37.86%
5-Day Price Return0.00%
EPS Normalized (Annual)$-62.19
ROA (5Y Avg)-72.55%
Month-to-Date Return5.91%
EBITD / Share (Annual)$-64.08
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-200.29%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-32.56
P/TBV (Quarterly)0.90x
P/B Ratio (Annual)0.71x
Book Value / Share (Annual)$9.70
Price vs S&P 500 (13W)-5.43%
Beta0.45x
Revenue / Share (TTM)$0.00
ROE (TTM)-166.53%
52-Week Low$4.95
Analyst Recommendations
Oct 2022
Nov 2022
Dec 2022
Jan 2023
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BCTXBriacell Therapeutics Corp. Common Shares | — | — | — | — | $4.02 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
BriaCell Therapeutics is a clinical-stage biotech company developing targeted cell-based immunotherapies for cancer. Lead program Bria-IMT is in end-stage clinical trials for breast cancer, while Bria-OTS offers personalized immunotherapy options for breast and prostate cancer. The company is evaluating combination therapy approaches through clinical collaborations.